Isthmus Partners LLC Acquires 16,505 Shares of Haemonetics Corporation $HAE

Isthmus Partners LLC lifted its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 36.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 61,702 shares of the medical instruments supplier’s stock after acquiring an additional 16,505 shares during the period. Isthmus Partners LLC owned approximately 0.13% of Haemonetics worth $3,007,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Parkside Financial Bank & Trust boosted its stake in Haemonetics by 11.6% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,461 shares of the medical instruments supplier’s stock valued at $109,000 after purchasing an additional 152 shares during the last quarter. Retirement Systems of Alabama lifted its holdings in shares of Haemonetics by 0.4% in the second quarter. Retirement Systems of Alabama now owns 61,401 shares of the medical instruments supplier’s stock valued at $4,581,000 after purchasing an additional 256 shares in the last quarter. Teacher Retirement System of Texas boosted its position in shares of Haemonetics by 3.9% during the second quarter. Teacher Retirement System of Texas now owns 7,636 shares of the medical instruments supplier’s stock valued at $570,000 after buying an additional 285 shares during the last quarter. Quantinno Capital Management LP boosted its position in shares of Haemonetics by 9.0% during the second quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock valued at $261,000 after buying an additional 289 shares during the last quarter. Finally, CWC Advisors LLC. grew its holdings in Haemonetics by 7.8% during the third quarter. CWC Advisors LLC. now owns 4,551 shares of the medical instruments supplier’s stock worth $222,000 after buying an additional 328 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Trading Up 0.9%

NYSE:HAE opened at $61.24 on Friday. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $87.32. The company has a current ratio of 1.75, a quick ratio of 1.15 and a debt-to-equity ratio of 1.01. The firm’s 50 day moving average is $71.94 and its 200 day moving average is $64.06. The stock has a market capitalization of $2.85 billion, a PE ratio of 16.87, a price-to-earnings-growth ratio of 1.27 and a beta of 0.28.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The business had revenue of $338.97 million during the quarter, compared to the consensus estimate of $331.90 million. During the same period last year, the business posted $1.19 earnings per share. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Sell-side analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on HAE shares. Barrington Research set a $94.00 price objective on shares of Haemonetics in a report on Friday, February 6th. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. JPMorgan Chase & Co. boosted their price target on shares of Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a report on Friday, December 12th. Raymond James Financial reiterated an “outperform” rating and issued a $90.00 price objective on shares of Haemonetics in a research note on Friday, November 14th. Finally, Needham & Company LLC cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $84.44.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.